Experience

Quotient Therapeutics

• Biotechnology Research
• 1 - 100 Employee

• Senior director, Head of Translational Biology and Pharmacology

  • Jan 2023 - 1 year

  Cambridge, Massachusetts, United States - Spearhead target validation across diverse disease indications encompassing autoimmune disorders, cancer, and metabolic diseases. Build in vitro and in vivo validation package ensuring the selection of promising lead candidates - Contribute to the company's strategy on resource distribution, target and pipeline prioritization and long-range planning - Manage a diverse team with distinct expertise. Foster collaboration and facilitate efficient progress towards common goals. -… Show more - Spearhead target validation across diverse disease indications encompassing autoimmune disorders, cancer, and metabolic diseases. Build in vitro and in vivo validation package ensuring the selection of promising lead candidates - Contribute to the company's strategy on resource distribution, target and pipeline prioritization and long-range planning - Manage a diverse team with distinct expertise. Foster collaboration and facilitate efficient progress towards common goals. - Coordinate efforts with scientific cofounders, engage in academic collaborations and manage CROs Show less



Fuhong Therapeutics

• Research head of Immunology

  • Mar 2021 - Dec 2022

  United States • Lead multiple immunology projects with a focus on systemic lupus erythematosus (SLE), lupus nephritis and IBD; transited lead SLE program from target proposal to candidate optimization stage within one year. • Lead the development of multiple in vitro models (ELISA, reporter cell assay, primary cell-based assays, etc.) and in vivo model systems (PD models, lupus disease models) to support target validation and candidate screening. • Lead the development of novel biologic-based platforms… Show more • Lead multiple immunology projects with a focus on systemic lupus erythematosus (SLE), lupus nephritis and IBD; transited lead SLE program from target proposal to candidate optimization stage within one year. • Lead the development of multiple in vitro models (ELISA, reporter cell assay, primary cell-based assays, etc.) and in vivo model systems (PD models, lupus disease models) to support target validation and candidate screening. • Lead the development of novel biologic-based platforms for site-directed drug release. • Lead the development of Dynamic Multiepitope Analysis (DMA), an inhouse AI-based platform for antibody drug design and evaluation. • Effectively manage internal and external collaborations to meet program goals and deliver results. • Lead a team of researchers; commit to each team member’s career development; received the Excellence in Leadership Award voted by employees. • Work with senior leadership team to develop research strategies. Show less



AbbVie

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Principal Research Scientist I

  • Nov 2019 - Oct 2021

  Cambridge, Massachusetts Lead a group of PhD and non-PhD scientists focusing on new target identification and validation. • Built a target triage pipeline to screen and identify novel targets. o Established and executed CRISPR-based genome-wide functional genomic screens in collaboration with Genomic Research Center. Executed validation screens in different cell types and assays. Identified hits and pushed the new targets into the discovery pipeline. o Led in vitro and in vivo effort to establish novel… Show more Lead a group of PhD and non-PhD scientists focusing on new target identification and validation. • Built a target triage pipeline to screen and identify novel targets. o Established and executed CRISPR-based genome-wide functional genomic screens in collaboration with Genomic Research Center. Executed validation screens in different cell types and assays. Identified hits and pushed the new targets into the discovery pipeline. o Led in vitro and in vivo effort to establish novel platforms using genetic tools. Established a variety of model systems including a hematopoietic stem cell-based system to specifically evaluate target biology in the in vivo immune system. Developed a number of models including autophagy models, fibrosis models, IBD models, PD models to study inflammation, humanized mouse system, etc.. o Involved in the functional analysis of patient-derived SNPs. Participated in transcriptomic and proteomic analysis of targets. • Led exploratory effort in investigating the biology of novel targets. Successfully built the in vitro and in vivo data package for early target projects. • Received multiple distinguished awards, which include Special Scientific Governing Board Award, President Award, Vice President Award and 3R Advancement Award.

• Senior Scientist III

  • May 2018 - Nov 2019

  Cambridge, Massachusetts Lead a group working on CRISPR based platform for new target identification and validation: in vitro and in vivo systems; functional genomic screens; individual target biology validation Champion early targets in Immunology Discovery

• Sr Scientist II

  • Sep 2012 - May 2018

  Worcester, USA Project leader in early discovery, drove project to phase 1 clinical trial CRISPR/Cas9-based genome editing for screening (new target ID) and confirmation study (target biology validation) Primary human T cells, myeloid cells, in vivo mouse models Autoimmune diseases, cancer immunotherapy



Harvard Medical School

• United States
• Higher Education
• 700 & Above Employee

• Postdoc Fellow

  • Apr 2009 - Sep 2012

  Boston Functional mechanisms of GARP/TGFb interaction



New York University

• Higher Education
• 700 & Above Employee

• Graduate student

  • 2006 - 2009

  New York city Role of GARP in Treg function